HER2 low breast cancer
NICE rejects Enhertu for HER2-low breast cancer over cost concerns
Anika Sharma
The remarkable efficacy data that initially earned AstraZeneca and Daiichi Sankyo’s Enhertu a standing ovation at the ASCO meeting last ...
Enhertu in Breast Cancer: A Breakthrough Treatment for HER2-Positive and HER2-Low
SG Tylor
This blog post will review how Enhertu in breast cancer works, how it is used, its benefits and risks, how ...
